[Primary hyperparathyroidism].
Primary hyperparathyroidism is the third most frequent endocrine disorder. The condition required for diagnosis is inappropriately elevated secretion of parathyroid hormone (PTH) with respect to calcemia. Most often, the disease is due to a parathyroid adenoma, i.e. a monoclonal benign parathyroid tumor, less often to a parathyroid hyperplasia. The main tumorogenic mechanisms currently proposed are a DNA rearrangement in the PTH locus (transposition of the PTH promoter upstream to Cyclin D1/PRAD 1 gene) and a mutation of the gene responsible for multiple endocrine neoplasia type I. The clinical presentation has strikingly evolved towards a milder, asymptomatic form, frequently diagnosed on systematic screenings. Though the mechanism of hypercalcemia is better understood, several hypothesis are still being considered about the regulation of tumoral PTH secretion: the role of the expression of calcium-receptor in parathyroid gland cells, vitamin D receptor and estrogen receptor polymorphisms, etc. Surgery is still advised for symptomatic forms of the disease, either because of a bone involvement, or because of an evolutive nephrolithiasis. In the near future, the new calcium-receptor agonists could be a relevant therapeutic approach.
Hertig
A
A
Service de physiologie, Hôpital Broussais, Paris.
Maruani
G
G
Paillard
M
M
Houillier
P
P
D006801:Humans; D006961:Hyperparathyroidism / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy; D018761:Multiple Endocrine Neoplasia Type 1 / Q000235:genetics; D010281:Parathyroid Hormone / Q000235:genetics / Q000378:metabolism
D010281:Parathyroid Hormone